Review Article
Colorectal Cancer Biomarkers: Where Are We Now?
Table 3
Summary of conventional and innovative CRC molecular diagnostic and screening methods.
| | Sensitivity (%) | Specificity (%) | Status |
| Tumor | | | | IHC | 83 | 90 | In use | MSI | 55–91 | 90 | In use | CIMP | N/A | N/A | Under evaluation | Stool | | | | gFOBT | 11–64 | 91–98 | In use | iFOBT | 56–89 | 91–97 | In use | Vimentin | 72.5–83 | 53–86.9 | In use | Multitarget stool test | 42.4 (advanced adenomas) 92.3 (CRC) | 986.6 | Clinical validation | Blood | | | | CEA | 30–63 | 63–100 | In use | CA 19-9 | 18–52 | 79–100 | In use | TIMP-1 | 55 | 95 | Clinical validation | CTCs | 32–94 | ND- 94 | Clinical validation |
|
|
For diagnosis of Lynch Syndrome [68]. ND: not determined; N/A: not applicable. [69], [70], and [71].
|